Literature DB >> 35382145

Iloprost infusion through elastomeric pump in the treatment of Raynaud's phenomenon and digital ulcers.

Maria Helena Fartura Braga Temido1, Manuel Gomes2, Francisco Parente1, Lèlita Santos1.   

Abstract

Introduction: Systemic sclerosis is a systemic autoimmune disease characterized by microangiopathy and fibroblast dysfunction resulting in fibrosis of the skin and internal organs. Raynaud's phenomenon and digital ulcers are the main clinical features of vascular involvement. Treatment with iloprost is recommended to reduce the frequency and severity of Raynaud's phenomenon attacks and to heal active digital ulcer. Classical forms of treatment require admission to a ward or day-hospital unit to ensure safety during infusion, causing disruption of the patient's normal daily life and resulting in significant costs with hospitalization. Nowadays, new portable devices, of which the elastomeric pump is an example, are becoming available in order to avoid hospitalization. Case reports: We describe five cases of patients with systemic sclerosis or mixed connective tissue disease and severe Raynaud's phenomenon/critical ischaemia or active digital ulcers that were successfully treated with iloprost infusion through elastomeric pump without experiencing any side effects. We present our unit's protocol for ambulatory infusion. Discussion/conclusion: Our case reports and a brief review of literature prove that iloprost infusion through elastomeric pump is safe, easy and well tolerated and might even improve patient compliance with treatment. Meanwhile, it may also decrease the economic burden of hospitalization with these patients.
© The Author(s) 2018.

Entities:  

Keywords:  Digital ulcers; Raynaud’s phenomenon; elastomeric pump; iloprost

Year:  2018        PMID: 35382145      PMCID: PMC8922585          DOI: 10.1177/2397198318765596

Source DB:  PubMed          Journal:  J Scleroderma Relat Disord        ISSN: 2397-1983


  4 in total

1.  Efficacy, safety and feasibility of intravenous iloprost in the domiciliary treatment of patients with ischemic disease of the lower limbs.

Authors:  R Polignano; C Baggiore; F Falciani; U Restelli; N Troisi; S Michelagnoli; G Panigada; S Tatini; A Farina; G Landini
Journal:  Eur Rev Med Pharmacol Sci       Date:  2016-09       Impact factor: 3.507

2.  Efficacy of a novel method of intravenous infusion of the prostaglandin analogue iloprost for the treatment of lower-limb critical ischemia: An open-label, nonrandomized study in two cohorts.

Authors:  Pierfrancesco Veroux; Massimiliano Veroux; Maurizio Macarone; Maria Giovanna Bonanno; Maria Giuseppina Tumminelli
Journal:  Curr Ther Res Clin Exp       Date:  2004-05

3.  A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA).

Authors:  Paolo Fraticelli; Giuseppe Pio Martino; Marta Murri; Massimo Mattioli; Armando Gabrielli
Journal:  Clin Exp Rheumatol       Date:  2017-08-31       Impact factor: 4.473

4.  Long Term Stability Evaluation of Prostacyclin Released from Biomedical Device through Turbiscan Lab Expert.

Authors:  Christian Celia; Marcello Locatelli; Felisa Cilurzo; Donato Cosco; Emanuela Gentile; Daniela Scalise; Maria Carafa; Cinzia Anna Ventura; Mathias Fleury; Christelle Tisserand; Renato C Barbacane; Massimo Fresta; Luisa Di Marzio; Donatella Paolino
Journal:  Med Chem       Date:  2015       Impact factor: 2.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.